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Handheld magnetic probe with 
permanent magnet and Hall sensor 
for identifying sentinel lymph 
nodes in breast cancer patients
Masaki Sekino1, Akihiro Kuwahata1, Tetsu Ookubo1, Mikio Shiozawa2, Kaichi Ohashi1,  
Miki Kaneko1, Itsuro Saito3, Yusuke Inoue1,4, Hiroyuki Ohsaki5, Hiroyuki Takei6 &  
Moriaki Kusakabe7,8
The newly developed radioisotope-free technique based on magnetic nanoparticle detection using a 
magnetic probe is a promising method for sentinel lymph node biopsy. In this study, a novel handheld 
magnetic probe with a permanent magnet and magnetic sensor is developed to detect the sentinel 
lymph nodes in breast cancer patients. An outstanding feature of the probe is the precise positioning 
of the sensor at the magnetic null point of the magnet, leading to highly sensitive measurements 
unaffected by the strong ambient magnetic fields of the magnet. Numerical and experimental results 
show that the longitudinal detection length is approximately 10 mm, for 140 μg of iron. Clinical tests 
were performed, for the first time, using magnetic and blue dye tracers—without radioisotopes—in 
breast cancer patients to demonstrate the performance of the probe. The nodes were identified through 
transcutaneous and ex-vivo measurements, and the iron accumulation in the nodes was quantitatively 
revealed. These results show that the handheld magnetic probe is useful in sentinel lymph node biopsy 
and that magnetic techniques are widely being accepted as future standard methods in medical 
institutions lacking nuclear medicine facilities.
Sentinel lymph node biopsy (SLNB) is performed to investigate tumor metastases and determine the appropriate 
sequence of care for breast cancer patients1–3. By performing SLNB, breast cancer patients can avoid unneces-
sary invasive procedures and the resulting side effects such as lymphedema, seroma, and numbness, associated 
with axillary node dissections. That is, SLNB provides a noninvasive treatment option. In general, breast cancer 
spreads predominantly via the lymphatic system, and the sentinel lymph node (SLN) is the first lymph node that 
receives the lymphatic drainage from the primary tumor site. Thus, it is essential to detect the SLNs in the proce-
dure of SLNB. To date, the standard technique for SLN detection is a “combined technique” that uses tracers of 
radioisotope nanocolloids (generally technetium 99 m: 99mTc) and blue dye, to identify the SLNs with a gamma 
probe4,5 and visual observation6, respectively7–13. The radioisotope technique, in particular, which has the highest 
detection rate for SLNs, is based on radiation detection and provides quantitative identification to determine the 
incision location transcutaneously. However, both methods have significant drawbacks. The visual observation of 
the blue dye by the surgeon is subject to their own discretion, which makes it a subjective assessment. Moreover, 
it may cause allegoric/anaphylactic reactions14. The radioisotope method may not be accessible for all patients, 
owing to the lack of radiation facilities in some medical institutions. Furthermore, the use of radioisotope tracers 
exposes patients as well as technicians to radiation. The development of new techniques to solve these issues in 
detecting SLNs in a clinical site is thus becoming necessary.
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Superparamagnetic iron oxide nanoparticles (SPIONs) are being widely used as contrast agents in magnetic 
resonance imaging (MRI) in medical institutions without radiation facilities. The particles injected into the 
human body for localizing the SLNs move into the SLNs via the lymphatic system and can be visualized using 
MRI. However, the limited availability of MRI facilities remains a key issue; without MRI facilities, only preop-
erative localization of the SLNs can be performed. This information is insufficient for intraoperative detection, 
considering that the shape of the breast may change with changes in posture during surgery.
In contrast, a handheld magnetometer can facilitate the intraoperative identification of SLNs by using SPIONs. 
A handheld magnetic probe with a superconducting quantum interference device (SQUID) provides highly sen-
sitive magnetic detection15 and has been used in clinical studies on mice16–18. However, it is difficult to introduce 
the magnetometer into the operation room, as it requires liquid nitrogen/helium as a refrigerant.
A handheld magnetometer that can be used at room temperatures, i.e., without a refrigerant, has been devel-
oped as a magnetic technique to detect the SLNs in breast cancer patients. A clinical study using the magneto-
meter and SPION tracers was performed on breast cancer patients19, and subsequent studies revealed that the 
magnetic technique was not inferior to the radioisotope technique20–25, which indicated that the technique could 
be a prospective standard method without any limitations. A meta-analysis (more that 1000 patients) of SLNB 
using the magnetic technique has reported that the mean identification rate was 97.1% (range 94.4–98.0)26, which 
is comparable to the radioisotope technique (96.8%). Among the magnetic techniques, there are two common 
methods used to generate the magnetic field required to magnetize the SPIONs: one uses an electromagnetic 
coil for generating an alternating magnetic field20–25 (as described by the many clinical trials using the Sentimag 
magnetometer). The other uses a permanent magnet for generating a direct magnetic field19 (as demonstrated by 
M. Shiozawa et al.). The benefit of using an electromagnetic coil is that the strength of magnetic field can be 
adjusted and the nonlinear magnetic characteristics can be utilized27,28. However, the disadvantage of this method 
is that it requires a large power supply to generate strong magnetic fields, which in turn leads to the need for a 
countermeasure for Joule heating. The relatively large power that is required intrinsically implies that the probe 
cannot be constructed without a power cable and power unit, which is a limitation (e.g., lack of the transporta-
bility and controllability) for installation into clinical sites to some extent. By contrast, the use of a magnet that 
requires the generation of moderately strong fields, in the order of 100 mT without the electricity, promoted the 
creation of the compact handheld magnetic probe system without the power cable, which facilitates easier intra-
operative detection because of its small size.
Obviously, while larger magnets can generate stronger magnetic fields, large-sized probes face issues related to 
transportability and controllability. To establish the magnetic technique using a permanent magnet, the optimum 
magnet size in the probe must be verified. In this study, numerical and experimental evaluations are performed to 
optimize the shape and size of the magnet and to reveal the sensitivity of the probe. We developed a novel hand-
held magnetic probe with a permanent magnet and a magnetic sensor for identifying the SLNs. This probe incor-
porated a unique outstanding feature for high-sensitivity measurements and displayed the measured magnetic 
fields quantitatively in units of μT. We performed the first ever clinical test with SPIONs and blue dye (without 
radioisotopes) tracers to demonstrate the performance of the prototype magnetic probe in SLNB for breast cancer 
patients. Figure 1(a) shows the principles behind the identification of SLNs using a handheld magnetic probe with 
a permanent magnet and magnetic sensor, which is a promising nonradioisotope method based on magnetic 
detection for breast cancer patients. The SPIONs are injected into the vicinity of the cancer lesion (e.g., subareolar, 
subcutaneous, or intradermal site), and they move into the SLNs through the lymph vessels. The SPIO tracers 
accumulated in the SLNs are magnetized by the magnetic fields of the permanent magnet enclosed in the head of 
the magnetic probe (Fig. 1(b)), and subsequently, the SLNs containing the magnetic nanoparticles are identified 
by measuring the magnetic fields newly generated from the magnetized nanoparticles19,20,29–32.
Results and Discussion
Magnetic technique for the SLNB using a handheld magnetic probe with a permanent magnet 
and magnetic sensor. Figure 1(b) illustrates the magnetic field lines of the ring-shaped permanent magnet 
(neodymium magnet, NF40) enclosed in the head of the magnetic probe. There are two magnetic null points 
where the magnetic flux density is zero: at the top and bottom of the magnet. A unique outstanding feature of 
this developed magnetic probe is that the magnetic sensor is located at the magnetic null point at the top of the 
magnet; thus, tiny variations in the magnetic fields can be detected without the offset attributes from the nonzero 
magnetic fields. Thus, the amplifier gain can be enhanced optimally for tiny magnetic signals
Figure 1(c) shows the magnetic characteristics of Resovist33 (magnetic fluid containing the SPIONs) measured 
using the SQUID MPMS-5S, Quantum Design, Inc., US, for various iron amount 140, 280, and 560 μg, corre-
sponding to 5, 10, and 20 μL of Resovist, respectively. Increasing the applied magnetic field strongly increases the 
magnetic moment of the SPIONs in the range of 0–50 mT, and the measured magnetic moments are clearly pro-
poronal to their amounts. The SPIONs can be fully magnetized by applying a magnetic field of approximately 50 
mT. These results show that the maximum magnetic susceptibility χmax is approximately 0.16. Here, the relation 
between B and H is µ µ µ χ= = +B H H(1 )r0 0 , where B is the strength of the magnetic field, H is the magnetic 
field, rμ . is the relative permeability, and μ0 is the permeability of free space. Thus, the relative permeability of the 
SPION is approximately 1.16. In the presence of a magnetic field of 50 mT, the magnetization of the magnetically 
saturated SPIO is approximately χ= = . ×M H 1 5 10 A/m3 .
Numerical evaluation of the characteristics of a handheld magnetic probe. In the SLNB using 
the magnetic technique, a permanent magnet and magnetic particles generate the magnetic fields. To evaluate 
the spatial distributions of the magnetic fields and the sensitivity characteristics of the magnetic probe, numerical 
calculations are carried out using the finite element method (FEM) (the detailed method is shown in supplemen-
tary Fig. S1).
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The two-dimensional distribution of the calculated longitudinal magnetic field (BZ) generated by the perma-
nent magnet (outer radius and length are 6.25 and 12 mm, respectively) is shown in Fig. 2(a) with a color contour 
range of ±50 mT. At Z = 10.4 mm on the probe axis (Z-axis, X = 0 mm), the strength of the magnetic field BZ is 
approximately 50 mT and the position of the magnetic null point is Z = 0.3 mm, as shown in Fig. 2(b). Figure 2(c) 
shows the distributions of the calculated magnetic fields BZ, with a contour range of ±1 μT, generated by 140 μg 
of iron (5 μL of Resovist) of magnetically saturated SPIONs, located at Z = 10.4 mm. Figure 2(d) shows that the 
strength of the magnetic field, ΔB, at the sensor position (magnetic null point) depends on the distance between 
the sensor and the SPIO position. The magnetic signal from the SPIONs decreases with an increase in distance: 
the magnetic fields fall strongly to 14% between 5 and 10 mm. For the actual use, the current sensitivity limit of 
the Hall sensor (NHE-520) is 1 μT as shown in Fig. 2(d), owing to the noise attributed to thermal fluctuations. 
Thus, the present sensor can detect magnetic signals of 140 μg of SPIONs located at a distance of 10.4 mm, which 
means that “the longitudinal detectable distance” is approximately 10 mm. We should also note that, there are 
sensors with higher sensitivities, which work at room temperature, such as the giant magneto-resistance (GMR) 
and magneto-impedance (MI) sensors. However, these sensors do not work successfully in the vicinity of a mag-
net because their magnetic characteristics may change due to the nonuniformity of the strong magnetic field28,29.
To determine the optimum size of the magnet, we evaluated the distance range for a field of 50 mT (Z50) 
generated by varying the size of the magnet for the full magnetization of SPIONs. Figure 2(e) and (f) show the 
relationship between the outer radius and the length of the magnet and the distance Z50 of the point where the 
longitudinal magnetic field, BZ, is 50 mT from the magnet surface, respectively. The distance Z50 increases linearly 
as the outer radius of the magnet increases. On the other hand, the increment of Z50 as a function of the magnet 
length saturates roughly at 12 mm length of the magnet. The result indicates that it is more effective to increase the 
outer radius rather than the length of the magnet for increasing the distance Z50. However, Resovist is sufficiently 
magnetized by a magnetic field of 50 mT. For example, even if the Resovist that is magnetically saturated under 
the strong magnetic field is located at a distance of 20 mm (in the case of the outer radius is 13 mm as shown in 
Fig. 2(e)), the magnetic signal from the Resovist is less than 1 μT, indicating that the signal cannot be detected by 
the Hall sensor. Moreover, a large magnet is associated with poor transportability and controllability. Thus, the 
optimum outer radius and length of the magnet are considered to be 6.25 mm and 12 mm, respectively, taking 
into account that producing a 50 mT at the distance of 10 mm away is sufficient to detect the SPIONs.
Development of a prototype handheld magnetic probe and experimental evaluation of sensi-
tivity characteristics. We developed a handheld prototype of a magnetic probe with a permanent magnet 
Figure 1. (a) Principle of the technique based on magnetic detection of SLNs using a handheld magnetic 
probe and magnetic nanoparticles for breast cancer patients. Injected magnetic nanoparticles accumulate in 
the SLNs via the axillary lymphatic system and are detected by a magnetometer. (b) Schematic of the magnetic 
field lines produced by the ring-shaped permanent magnet. There are two magnetic null points on the surface 
of the magnet along the axis. The magnetic sensor is located at a magnetic null point. (c) Superparamagnetic 
characteristics of Resovist (Ferucarbotran); the magnetic moment measured by the SQUID apparatus as a 
function of the applied magnetic field from −300 to 300 mT.
www.nature.com/scientificreports/
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and Hall sensor and evaluated its sensitivity experimentally. As described above, it is essential that the sensor 
is located correctly at the magnetic null point, for obtaining high-sensitivity measurements without the off-
sets caused by the background magnetic fields, which is a unique outstanding feature of our magnetic probe. 
However, the spatial variations of the magnetic fields are too steep around the magnetic null point, 158 mT/mm 
[see Fig. 2(b)]. We utilize a newly developed apparatus (see supplementary Fig. S2) to arrange the sensors with 
spatial resolutions of less than a few micrometers; Consequently, the Hall element inside the sensor can be fixed at 
the magnetic null point correctly, with a field resolution of 1 μT, which is almost equivalent to 0.01 μm.
Figure 3(a) shows the detected signal dependence on the positional displacement of the Hall element inside 
the sensor. At approximately 0.3 mm—the magnetic null point (Fig. 2(b))— the detected signal reaches its highest 
value, reading 50 μT, for 140 μg of iron. When the Hall sensor position deviates from the magnetic null point, 
the detected signal decreases gradually because of the poor linearity of the InSb Hall element in the presence of 
strong magnetic fields (approximately 20 mT) as shown in Fig. 3(a). The spatial gradient of the magnetic field 
Figure 2. Numerical results: (a) Two-dimensional distribution of the longitudinal magnetic field BZ of the 
permanent magnet. (b) BZ of the magnet on the Z-axis (X = 0 mm). ∇B (dBZ/dz) is approximately 158 mT/mm 
around the magnetic null point (Z = 0.3 mm). (c) Two-dimensional distribution of BZ of 140 μg of iron (5 μL 
of Resovist) of fully magnetized SPIO located at (X, Z) = (0, 10.4) mm. (d) Magnetic field strength ΔB at the 
sensor position as a function of the distance from the magnetic sensor to the SPIONs location on the Z-axis. 
Red dotted line represents the sensor detection limit of 1 μT. Relationships between (e) the outer radius and  
(f) the length of the magnet, and the distance Z50 of the point where the BZ of the magnet is 50 mT from the 
magnet surface.
Figure 3. (a) Signals detected with 140 μg of iron (5 μL of Resovist), as functions of the Hall element position: 
the gray dotted line shows that the magnetic null point is at approximately 0.3 mm. (b) Measured signals for four 
different volumes, 56, 140, 280, and 560 μg of iron. The red dotted line shows the detection limit of the sensor.
www.nature.com/scientificreports/
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around the magnetic null point is approximately 158 mT/mm, as shown in Fig. 2(b). Thus, the sensor must be 
fixed within the error of ±0.1 mm, which is equivalent to ±15.8 mT, to maintain its high sensitivity. To investigate 
the manufacturing error, that is the reproducibility, we made five probes. As a result, the error was 2 ± 3 μm (a 
few mT) and was sufficiently small to obtain highly sensitive measurements. The previous magnetometer that 
consisted a permanent magnet and permalloy has a similar feature that in the sensor is located at the magnetic 
null point by utilizing the arrangement of the inner and outer permalloy, and the clinical study using the probe 
was successful for the detection of the nodes19. However, there was no reproducibility, to some extent, regarding 
the correct arrangement of the sensor location relatively to the inner, outer permalloy, and magnet. Therefore, we 
developed the simple magnet configuration without permalloy in this study to establish the correct arrangement 
of the null point at the sensor location.
Figure 3(b) shows the detected signals from different amounts of SPIONs, 56, 140, 280, and 560 μg, as func-
tions of the distance between the surface of the probe head and the SPIONs. The measured magnetic flux density 
increased with increasing the amount of SPIONs, and the detectable length was 7, 9, 11, and 15 mm for 56, 140, 
280, and 560 μg, respectively, which also agrees well with the numerical results as shown in Fig. 2(d), by taking 
into account the distance between the sensor and the surface of the probe head [see supplementary Fig. S3a].
Clinical trials with SPIONs and blue dye tracers. We performed a small clinical trial on six breast can-
cer patients in the Sin-Oyama City Hospital in Japan, in accordance with the protocols approved by the clinical 
community, to verify the feasibility of the developed handheld magnetic probe (see supplementary Fig. S3c). 
SPIONs (Resovist, 1.6 mL) and blue dye tracers (Patent Blue V, 3 mL) were injected into the subareolar region 
as shown in Fig. 4(a), as per a new combined technique without radioisotopes. After injection, surgeons mas-
saged the vicinity of the injection site for 10 min to promote the lymphatic flow and tracer accumulation. The 
surgeons subsequently performed transcutaneous detection of the SLNs using the magnetic probe to determine 
the resection location, as shown in Fig. 4(b); the strength of the magnetic signal was approximately 1–2 μT in the 
transcutaneous detection. Eventually, the surgeons succeeded in finding the SLNs by magnetic detection using the 
probe and visual observation of the blue and/or brown colored nodes and excised the nodes as shown in Fig. 4(c). 
After extracting the SLNs, they confirmed that there were no SLNs in the axilla through scanning with the mag-
netic probe; the measured magnetic signal was less than 1 μT (the detection limit). The SLNs were successfully 
detected using the magnetic technique in four patients. The strength of the magnetic signal from the nodes was 
approximately 11 ± 5 μT in situ and the ex vivo measurements. Out of these four cases, we succeeded in the trans-
cutaneous detection of the lymph nodes in three cases. In the other case, the iron amount measured by SQUID 
was approximately 30 μg (1.1 μL of Resovist), which was too small to be detected from the skin surface using the 
prototype magnetic probe. Because the iron accumulation and node location strongly depend on the patient’s 
characteristics such as age and BMI, it may not be possible to detect the nodes using the prototype probe in some 
cases. Currently, it is preferred that the probe is utilized for identifying the SLNs using in/ex vivo measurements 
Figure 4. Procedure of the clinical test for the magnetic technique involving SPIO and blue dye tracers, using 
the handheld magnetic probe with a permanent magnet and Hall sensor for SLNB; (a) injection of SPIO tracers 
around the subareolar region, (b) transcutaneous detection of the SLNs before incision, and (c) SLNs detection 
and excision in the axilla after incision. In the injection phase (a), the blue dye tracer is injected at the same 
location after the injection of the SPIO tracer.
www.nature.com/scientificreports/
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rather than transcutaneous measurement. Further studies are required to improve the sensitivity of the probe and 
the strong magnetization of the nanoparticles.
It is clearly found that the blue and brown colors in an example of the excised node are caused by the blue dye 
and Resovist as shown in Fig. 5(a). To evaluate correctly the accumulation of SPIONs in the six excised lymph 
nodes detected by the magnetic probe from four patients, the magnetic moments of the nodes were measured 
using the SQUID apparatus as shown in Fig. 5(b). Note that the volume of the measured SLN is half of the volume 
of the excised nodes, and consequently, the amount of iron in the excised node is double the value calculated from 
Fig. 5(b). By comparing with the SPIO sample of 140 μg of iron, it is revealed that the amount of iron contained 
in the excised SLNs is approximately 140 ± 80 μg of iron (5 ± 3 μL of Resovist); 210 240, 77, 30, 200, and 91 μg for 
each SLN. We also revealed, for the first time, that the iron content contained in the SLNs of breast cancer patients 
is approximately 0.3% of the injection volume of 1.6 mL (44.6 mg of iron). This is an important knowledge to 
optimize the injection amount of magnetic nanoparticles for future operations. The large amount of injection 
would cause the huge susceptibility artifact around the injection site on magnetic resonance imaging (MRI) after 
surgical operations, which is a drawback in SLNB using magnetic nanoparticles34.
The magnetization of the excised nodes as shown in Fig. 5(b) are not completely consistent with the reference 
data (140 μg of iron), and the difference is contributed by the diamagnetic component of the biomedical tissues. 
For the other reason, the magnetic characteristics of the nanoparticles might change in the lymph node because 
the aggregation or disaggregation of the particle may occur in the lymph node. Further research is need to obtain 
the clear evidence, e.g., the particle concentration.
Figure 5(c) shows the histopathology of the extracted node. The blue area shows the iron deposition, and it 
is localized in the cortex of the lymph node. The metastasis is also confirmed in one node. It is reported that the 
SPIO hardly accumulates in the node containing the metastasis35. However, according to the clinical trials per-
formed by J.-L. Houepeau et al.25, the detection rate of the normal nodes (~97%) was almost consistent with that 
of the carcinogenic nodes (~98%), which suggests that the sentinel nodes contains the sufficient amount of iron 
to detect the magnetic probe even if there is metastasis in the nodes. That node was detected in this study as well 
as previous studies.
To further investigate the distribution of the SPIONs in the SLNs, we measured the magnetic signal from a 
large phantom that simulates the size of the SLNs: the typical long and short-axis lengths of the SLNs are 12.4 
and 7.4 mm, respectively36, and their volume is approximately 350 μL (Resovist 5 μL and saline 345 μL). In the 
ex vivo measurements, the magnetic signals detected from the small (Resovist 5 μL only) and the large phantom 
are 40 and 5 μT, respectively. Meanwhile, when the magnetic probe is in contact with the excised SLNs, the meas-
ured signal is 11 ± 5 μT, which is larger than the signal detected from the diluted 350 μL of large phantom and is 
smaller than the signal from the 5 μL of small phantom. Therefore, the SPIONs may be located on the surface of 
Figure 5. (a) Blue color of Patent blue and brown color of Resovist (Ferucarbotran) in the excised node. 
(b) Magnetic moments of a half volume of the excised node and 140 μg of SPIONs measured by the SQUID 
apparatus. (c) Histopathology of the excised node. The distribution of iron staining (Perl’s Prussian blue) is 
generally in the cortex of the node. Metastasis was observed in one excised node.
www.nature.com/scientificreports/
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the SLNs, instead of being distributed uniformly within the SLNs and/or localized in the centers of the SLNs, as 
shown in Fig. 4(c).
Conclusions
We developed a novel handheld magnetic probe with a permanent magnet and a Hall magnetic sensor to detect 
the SLNs containing SPIONs in breast cancer patients. An outstanding feature of the probe was the correct posi-
tioning of the sensor with respect to the magnetic null point of the permanent magnet, which resulted in highly 
sensitive measurements without the influence of ambient strong magnetic fields from the neodymium magnet. 
Numerical and experimental results showed the magnetic probe could detect the magnetic signal of the SPIONs 
of 140 μg of iron in 5 μL of Resovist when separated by a distance of 10 mm, i.e., the longitudinal detection length 
was 10 mm. We conducted the first ever clinical study on the combined use of magnetic and blue dye tracers 
(without radioisotope) for breast cancer patients in the Sin-Oyama City Hospital, to verify the performance of 
magnetic detection using the magnetic probe. We successfully detected the SLNs containing the magnetic nano-
particles through transcutaneous and ex vivo measurements. The newly developed magnetic probe was found to 
be beneficial for the identification of the SLNs. The clinical test also revealed that the uptake of the magnetic nan-
oparticles into the nodes was approximately 140 ± 80 μg, which was equivalent to 0.3% of the injection amount of 
44.6 mg (1.6 mL of Resovist). Moreover, the SPIONs were mostly localized in the cortex of the nodes.
Although the prototype magnetic probe has a cable for the connection of the measurement and driving cir-
cuits, in the near future, we plan to further develop our probe and make it more compact without the cable and 
small unit by merging the probe body and the driving circuit, because the probe does not require a large power 
supply for the generation of magnetic fields. This will facilitate straightforward installation in all medical institu-
tions with/without nuclear facilities30,31. We believe that this is the main strength of our handheld magnetic probe 
compared to a magnetometer that uses an electromagnet coil (e.g., Sentimag magnetometer20–25). The magnetic 
technique provides a minimally invasive method for the SLN localization in cancer patients, thereby, improving 
the quality of life of the patients.
Material and Methods
Resovist (magnetic fluid containing SPIONs). The SPIONs injected into the patient’s body must be 
established safe for humans. The SPIO tracer we employ is a ferucarbotran, Resovist32 (44.6 mg of iron in 1.6 mL 
vial: iron concentration is approximately 28 mg/mL), Bayer Schering Pharma, DE, which was originally devel-
oped as a contrast agent for use in MRI. Resovist consists of a carboxydextran shell to stabilize the magnetic 
nanoparticle aggregations, and its size is approximately 60 nm37. Therefore, the magnetic tracers are suited for 
accumulation in the lymph nodes via the axillary lymphatic system: the SPIONs accumulates into the sentinel 
node via lymph vessels because macrophages in the nodes capture the nanoparticles, although it does not have the 
functionalization to attach actively to carcinogenic cells.
Numerical simulations. Postprocessor (FEMAP; Numerical Simulation Tech Co., Ltd., JP) and solver 
(PHOTO-Series: Photon Co., Ltd., JP) were used in the FEM to create the model and perform the numerical 
analysis (see supplementary Fig. S1). The simulation parameters are as follows. The inner radius and outer radius 
of the ring-shaped permanent magnet are 2.5 mm and 6.25 mm (varied outer radii are used in Fig. 2 (e)), respec-
tively. The inner radius of the magnet is 2.5 mm and the length of the magnet is 12 mm (different lengths are used 
in Fig. 2 (f)). The nanoparticle, equivalent to a volume of 5 μL, is a sphere of radius 1.05 mm. The relative per-
meability of the Neodymium magnet, SPIONs (Resovist), and air are 1.05 (standard value), 1.16 (from Fig. 2(c)), 
and 1, respectively, remain constant. The coercive forces of the magnet and SPIONs are 1000 (standard value) and 
1.5 kA/m (from Fig. 2(c)), respectively. The total element number is approximately 500,000 and the maximum 
spatial resolution (the minimum element size) is 0.1 mm. Note that the element size increases with the increase in 
the distance from the magnet and SPIONs: the sizes close to the magnet and SPIONs are approximately 0.1 mm, 
and the element sizes around the simulation boundaries are approximately 1 mm. To obtain accurate numerical 
results, the simulation area should be sufficiently large, (X, Z) = (0–300, −300–300 mm) compared to the sizes 
of the magnet and SPIONs. The existence of parallel magnetic fields alone at the boundary can be allowed in the 
initial state of the calculations, which is the boundary condition for the numerical simulations.
Handheld magnetic probe. A neodymium magnet (NF40, with typical coercive force of approximately 
950–1000 kA/m) manufactured by Sagami Chemical Metal Co., Ltd. was used for the magnetization of the 
SPIONs. The nonmagnetic probe shaft made of brass was inserted into the center hollow of the ring-shaped mag-
net. The Hall sensor (NHE520, high-output–type Hall element using evaporated InSb film) was fixed using glue on 
the edge of the shaft and the Hall element in the sensor was located at the magnetic null point. Note that the InSb 
Hall element is usually used for high-sensitivity measurements in low magnetic fields (typically less than 20 mT). 
The diameter of the probe head was 18 mm, and the probe housing was made of acrylonitrile-butadiene-styrene 
(ABS) resin. Conventional electric circuits were used for the measurement of the magnetic signals. The detected 
signals were displayed on the panel in real time during the intraoperative identification and in vitro experiments 
(see supplementary Fig. S3).
Measurements using magnetic phantom for evaluating the developed probe. A carboxydextran- 
coated SPION, ferucarbotran32, was employed for use in small magnetic phantoms with iron amounts 140, 280, 
and 560 μg (volumes of 5–20 μL) for in vitro characterization. The SPIONs were fixed with glue in small plas-
tic containers and the magnetic phantoms of various volumes were constructed. The probe head was fixed and 
the SPIO phantom could be displaced using the linear XY stage. The driving voltage of the Hall sensor was 1 V 
(current was approximately 20 mA) and the amplifier (CA461F2, NF Corporation, JP) gain was 40 dB during 
the measurements. To simulate the SLNs of breast cancer patients, a larger size phantom was fabricated. The 
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spherical phantom of 350 μL, which simulated the typical sizes of SLNs with long and short-axis lengths of 12.4 
and 7.4 mm, were constructed using 5 μL of Resovist and 345 μL of saline.
Clinical tests and evaluations of SLNs. To demonstrate the performance of the developed magnetic 
probe system, clinical tests were conducted on six breast cancer patients, whose average age was 69.3 ± 6.7, in 
accordance with the protocols for the care of patients and scientific purposes. The protocols were approved 
by the ethical community of the Shin-Oyama City Hospital (Date of registration: 15/10/2009) and the clinical 
trial was retrospectively registered within UMIN (University Hospital Medical Information Network)-CTR in 
Japan (Date of registration: 01/12/2017, Registration number: UMIN 000030127). UMIN-CTR is the registry 
that currently meet the criteria of the WHO registry network. All study participants provided informed con-
sent. Resovist (SPION; 1.6 mL of magnetic fluid containing 44.6 mg of iron) and Patent blue V (blue dye; 1%, 
3 mL) were injected (after induction of anesthesia) into the subareolar region in all breast cancer patients partic-
ipating in the tests. If surgeons could not detect the node using the magnetic probe transcutaneously, the node 
location was estimated with the traditional method; the resection location was determined with an ultrasound 
measurement and/or surgeon’s estimation (the locations are typically 1-2 cm below the hairline in the axilla). 
After the estimation, the surgeon resected the skin and detected the node inside the axilla using the magnetic 
probe. Excised nodes were measured using the SQUID apparatus, for the quantitative evaluation of the uptake 
of SPIONs in the SLNs. Histopathology of the lymph nodes was performed after the surgical operation. The 
extracted formalin-fixed lymph nodes were processed by thin slicing and paraffin wax embedding. The iron dep-
osition and tumor metastasis in the nodes were then assessed using Perl’s Prussian blue (Sigma-Aldrich, Poole, 
UK) staining and Hematoxylin and Eosin (H&E) staining, respectively.
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